The team of Professor Jia Jianping of Xuanwu Hospital of Capital Medical University passed a 20-year studyFor the first time, the dynamic changes of cerebrospinal fluid and imaging biomarkers in Alzheimer's disease (AD) from the asymptomatic period to the symptomatic stage were revealed, and the key time nodes of physiological and pathological changes in the onset of AD were clarifiedIt provides a time window for new anti-AD drugs targeting related pathological proteins such as amyloid.
On February 22, the relevant results** were published in the New England Journal of Medicine, which is the first time that a Chinese scholar in the field of AD has published a research-based paper in the journal.
Internet**, not related to the text) AD is usually divided into familial Alzheimer's disease (FAD) and sporadic Alzheimer's disease (SAD). Patients have a long period of asymptomatic disease before being diagnosed with AD, which is the first window period to prevent the development or reversal of AD, and the recognition of this stage relies on biomarkers.
Jia Jianping said that most of the current research on AD biomarkers is conducted in FAD. Studies have shown that A in SAD is different from FAD, suggesting that the biomarkers of SAD may have different trajectories, and the biomarker** model obtained from FAD studies may not be applicable to SAD populations.
Jia Jianping introduced,This study is the world's largest and longest-lasting longitudinal cohort study reflecting changes in biomarkers prior to AD diagnosis. This study has changed the status quo of applying SAD by the time of appearance of FAD biomarkers, and provides strong evidence for ultra-early diagnosis and precise intervention of AD.
*:Technology**.